MetaCap

Ionis Pharmaceuticals (IONS) vs Liquidia (LQDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Liquidia (LQDA) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 87.0% versus a loss of 65.1%. Over five years, LQDA leads with a +1224.3% price change compared with -8.5% for IONS. Liquidia is the larger company by market cap ($4.90 billion vs $4.43 billion), about 1.1 times the size.

Ionis Pharmaceuticals converts more of its revenue into profit, with a net margin of -40.4% versus -43.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IONS-65.07%LQDA+86.98%
+227%+74%-79%
Nov 21, 20251 yearNov 20, 2026
IONS-16.91%LQDA+1177.70%
+2120%+1000%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IONS versus LQDA key metrics
MetricIONSLQDA
Share price$26.58$54.43
Market cap$4.43B$4.90B
1-day change-2.35%-3.88%
YTD return-66.40%+57.81%
1-year return-65.07%+86.98%
5-year return-8.50%+1224.33%
Forward P/E—15.12
EPS (TTM)$-3.35$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$943.71M$158.32M
Revenue growth (YoY)+33.83%+1031.18%
Net income (latest FY)$-381.39M$-68.92M
Gross margin98.31%—
Operating margin-40.45%-32.45%
Net margin-40.41%-43.53%
52-week high$86.74$93.61
52-week low$26.53$22.31
Distance from 52-week high-69.36%-41.85%
Analyst consensusbuybuy
Avg. price target upside+155.19%+21.50%
Average volume3.91M3.52M
Shares outstanding166.55M90.11M
Employees1,485216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LQDA has outperformed IONS by 152.0 percentage points over the past year.
  • Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs +33.83%).

About Ionis Pharmaceuticals

IONS stock →

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).

Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

IONS vs LQDA FAQ

Which is bigger, Ionis Pharmaceuticals or Liquidia?

Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.43B for Ionis Pharmaceuticals (IONS).

Which stock has performed better over the past year, IONS or LQDA?

LQDA returned +86.98% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.

Are Ionis Pharmaceuticals and Liquidia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons